81 related articles for article (PubMed ID: 1411641)
1. The role of epipodophyllotoxin derivatives in bladder cancer.
Serretta V; Ingargiola GB; Pavone-Macaluso M
Semin Oncol; 1992 Apr; 19(2 Suppl 6):81-4. PubMed ID: 1411641
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.
Schulman CC; Robinson M; Denis L; Smith P; Viggiano G; de Pauw M; Dalesio O; Sylvester R
Eur Urol; 1982; 8(4):207-12. PubMed ID: 6807679
[TBL] [Abstract][Full Text] [Related]
3. EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma.
Schulman CC; Rozencweig M; Staquet M; Kenis Y; Sylvester R
Eur Urol; 1976; 2(6):271-3. PubMed ID: 829223
[TBL] [Abstract][Full Text] [Related]
4. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
5. New chemotherapies for ovarian cancer. Systemic and intraperitoneal podophyllotoxins.
Muggia FM; Russell CA
Cancer; 1991 Jan; 67(1 Suppl):225-30. PubMed ID: 1984824
[TBL] [Abstract][Full Text] [Related]
6. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.
Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V
Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645
[TBL] [Abstract][Full Text] [Related]
7. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm B; Sehested M; Jensen PB
Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
[TBL] [Abstract][Full Text] [Related]
8. [Instillation chemotherapy with peplomycin in superficial bladder cancer: clinical study on the effects of the direct antitumor activity and of the prophylaxis of recurrence].
Sonoda T; Osafune M; Matsuda M; Usami M
Hinyokika Kiyo; 1988 Mar; 34(3):574-81. PubMed ID: 2455442
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
10. Cooperative studies of chemoprophylaxis after transurethral resection of bladder tumors.
Pavone-Macaluso M; Tripi M; Ingargiola GB
Cancer Chemother Pharmacol; 1983; 11 Suppl():S16-21. PubMed ID: 6416698
[TBL] [Abstract][Full Text] [Related]
11. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
[TBL] [Abstract][Full Text] [Related]
12. Teniposide in the treatment of small cell lung cancer: a review.
Hansen HH; Dombernowsky P; Hansen M; Bork E
Semin Oncol; 1992 Apr; 19(2 Suppl 6):65-8. PubMed ID: 1329227
[TBL] [Abstract][Full Text] [Related]
13. The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancer.
Giaccone G; Splinter TA; Kirkpatrick A; Dalesio O; van Zandwijk N; McVie JG
Semin Oncol; 1992 Apr; 19(2 Suppl 6):98-102. PubMed ID: 1329231
[TBL] [Abstract][Full Text] [Related]
14. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
Flamm J; Kühnel W; Dona S
Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study.
Schulman C; Sylvester R; Robinson M; Smith P; Lachand A; Denis L; Pavone-Macaluso M; De Pauw M; Staquet M
Recent Results Cancer Res; 1978; 68():338-45. PubMed ID: 111322
[TBL] [Abstract][Full Text] [Related]
16. The biology and treatment of superficial bladder cancer.
Torti FM; Lum BL
J Clin Oncol; 1984 May; 2(5):505-31. PubMed ID: 6427417
[TBL] [Abstract][Full Text] [Related]
17. [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer].
Miki T; Nonomura N; Kojima Y; Okuyama A; Nakano E; Kiyohara H; Fujioka H; Koide T; Wakatsuki A; Kuroda H; Sugao H; Seguti T; Takeyama M; Yamaguchi S
Hinyokika Kiyo; 1997 Dec; 43(12):907-12. PubMed ID: 9488944
[TBL] [Abstract][Full Text] [Related]
18. [Progress in the internist treatment of bladder tumors].
Baumgartner G
Wien Med Wochenschr; 1982 Jul; 132(13-14):305-12. PubMed ID: 6814073
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group.
Dalesio O; Schulman CC; Sylvester R; De Pauw M; Robinson M; Denis L; Smith P; Viggiano G
J Urol; 1983 Apr; 129(4):730-3. PubMed ID: 6405056
[TBL] [Abstract][Full Text] [Related]
20. [A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer].
Hashimura T; Shirahase T; Inoue T; Yamasaki T; Terada N; Ogura K; Arai Y; Hida S; Ueda T
Hinyokika Kiyo; 2005 Jul; 51(7):439-42. PubMed ID: 16119805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
